Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised double-blind phase 3 trial

Lancet Oncol.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators.

doi: 10.1016/

Gastrointestinal Cancer

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study

Eur J Cancer.

Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F

doi: 10.1016/j.ejca.2020.04.048.

SPECIAL REPORT

Gastrointestinal Cancer

Failure is not final: rechallenge with Cetuximab as a good treatment option in RAS-wild-type tumours^1–3

This publication was supported by Merck (Schweiz) AG.

Gastrointestinal Cancer

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials

Eur J Cancer.

Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ

doi: 10.1016/j.ejca.2020.02.048.

Gastrointestinal Cancer

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

JAMA Oncol.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V

doi: 10.1001/

Gastrointestinal Cancer

Le cétuximab, un inhibiteur de l’EGFR, constitue une bonne option thérapeutique lors de CCRm avec tumeurs RAS wild-type

Article rédigé avec le soutien de Merck (Suisse) SA.

Gastrointestinal Cancer

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Lancet Oncol.

Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C

doi: 10.1016/S1470-2045(19)30827-7.

Gastrointestinal Cancer

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

Clin Colorectal Cancer.

Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H

doi: 10.1016/j.clcc.2016.07.003

Related content

Recent Developments in Metastatic Breast Cancer

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised double-blind phase 3 trial

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study

Failure is not final: rechallenge with Cetuximab as a good treatment option in RAS-wild-type tumours1–3

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Le cétuximab, un inhibiteur de l’EGFR, constitue une bonne option thérapeutique lors de CCRm avec tumeurs RAS wild-type

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

Failure is not final: rechallenge with Cetuximab as a good treatment option in RAS-wild-type tumours^1–3